cilastatin has been researched along with Ventilator-Associated Pneumonia in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Alarcón, T; Girón, RM; Gómez-Punter, RM; Ibáñez, A | 1 |
| Baccouche, N; Bahloul, M; Bouaziz, M; Chaari, A; Chtara, K; Hammami, A; Medhioub, F; Mnif, B; Pham, T | 1 |
| Bai, KJ; Hsieh, TC; Hsu, CW; Jean, SS; Lam, C; Lee, WS | 1 |
| Chen, J; Mody, SH; Shorr, AF; Zilberberg, MD | 1 |
| Cox, JC; Drachman, DA; Hibbard, ML; Kopelman, TR; Maly, TJ; Matthews, MR; O'Neill, PJ; Quan, AN; Vail, SJ | 1 |
| Chuang, YC; Cooper, CA; Dartois, N; Datsenko, O; Dukart, G; Dzyublik, O; Freire, AT; Gandjini, H; Glumcher, F; Kim, MJ; Korth-Bradley, JM; Maroko, RT; Melnyk, V | 1 |
| Chastre, J; Cirillo, I; Clavel, M; Kaniga, K; Kimko, H; Kollef, MH; Michiels, B; Redman, R; Restrepo, MI | 1 |
| Martin-Loeches, I; Torres, A | 1 |
| Cooper, A; Joshi, M; Kassira, W; McCarthy, M; Metzler, M; Olvey, S | 1 |
| Archontoulis, N; Giamarellos-Bourboulis, EJ; Giamarellou, H; Mega, A; Pavleas, I; Rigas, K; Thomopoulos, G; Vernikos, P | 1 |
1 review(s) available for cilastatin and Ventilator-Associated Pneumonia
| Article | Year |
|---|---|
New evidence in severe pneumonia: imipenem/ cilastatin/relebactam.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cilastatin; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Imipenem; Patient Acuity; Pneumonia, Ventilator-Associated; Randomized Controlled Trials as Topic | 2022 |
4 trial(s) available for cilastatin and Ventilator-Associated Pneumonia
| Article | Year |
|---|---|
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Cross Infection; Double-Blind Method; Drug Combinations; Hospital Mortality; Humans; Imipenem; Microbial Sensitivity Tests; Minocycline; Pneumonia; Pneumonia, Ventilator-Associated; Tigecycline; Treatment Outcome | 2010 |
A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cilastatin; Doripenem; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imipenem; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Ventilator-Associated; Young Adult | 2012 |
Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia.
Topics: Anti-Bacterial Agents; Cilastatin; Cross Infection; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Protease Inhibitors; Tazobactam; Tobramycin; Treatment Outcome | 2006 |
Impact of carbapenem administration on systemic endotoxemia in patients with severe sepsis and Gram-negative bacteremia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; C-Reactive Protein; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Endotoxemia; Female; Gram-Negative Bacterial Infections; Humans; Imipenem; Interleukin-6; Lipopolysaccharides; Male; Middle Aged; Pneumonia, Ventilator-Associated; Sepsis | 2006 |
6 other study(ies) available for cilastatin and Ventilator-Associated Pneumonia
| Article | Year |
|---|---|
Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Colistin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Minocycline; Pneumonia, Ventilator-Associated; Prognosis; Retrospective Studies; Salvage Therapy; Survival Analysis; Tigecycline; Tunisia | 2015 |
Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of cl
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Female; Hospital Mortality; Humans; Imipenem; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Pneumonia, Ventilator-Associated; Salvage Therapy; Sulbactam; Taiwan; Tigecycline; Treatment Outcome | 2016 |
Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Cost-Benefit Analysis; Doripenem; Drug Combinations; Humans; Imipenem; Length of Stay; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Quality-Adjusted Life Years; Young Adult | 2010 |
Empiric, broad-spectrum antibiotic therapy with an aggressive de-escalation strategy does not induce gram-negative pathogen resistance in ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Ventilator-Associated; Retrospective Studies; Tobramycin | 2010 |
Doripenem: excess mortality.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Early Termination of Clinical Trials; Evidence-Based Medicine; Humans; Imipenem; Pneumonia, Ventilator-Associated; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
A week seems to be weak: tailoring duration of antibiotic treatment in Gram-negative ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Female; Humans; Imipenem; Male; Pneumonia, Ventilator-Associated | 2013 |